Aino Health, the Swedish digital health platform, reported a drop in second-quarter net sales compared with the same quarter a year earlier, attributing the decrease primarily to postponed customer project starts that affected when revenue could be recognised. Reported net sales for the quarter were SEK 6.70 million.
The company recorded a wider loss after financial items in the quarter compared with the prior-year period. Management said the timing of customer implementations was the principal driver behind the revenue shortfall for the quarter, as projects that were expected to begin did not start as planned.
During the quarter Aino Health signed new customer agreements amounting to approximately 5,500 subscriptions. The firm noted that the financial contributions from these contracts will not be immediate; implementations are scheduled for later in 2026 and into early 2027, so revenue from those subscriptions will materialise gradually as the rollouts proceed.
Management also highlighted a constrained cash position that necessitated strict cost control measures. Those constraints limited the pace at which the company could make growth investments during the quarter, potentially delaying activities that would otherwise accelerate revenue conversion from the customer pipeline.
A public tender offer for all shares in Aino Health is currently in progress, with the acceptance period open until Aug. 10, 2026. The company reiterated that the timing and scope of its international expansion efforts will depend on securing additional financing.
Looking ahead, Aino Health identified several factors it will monitor closely in the coming quarters: the scheduling of planned implementations, levels of customer churn, and the transaction costs associated with business activity. The company said those elements will be important to revenue recognition and overall financial performance as it moves forward.
Overall, the quarter reflected delayed project starts and tighter cash management, while a meaningful pipeline of signed subscriptions exists whose financial impact will be felt once the planned implementations begin in late 2026 and early 2027.